Podcasts about gastroenterology and hepatology

Guest: Juan P. Rocca, M.D., MHA On this episode of Advances in Care, host Erin Welsh hears from Dr. Juan P. Rocca, a transplant surgeon at NewYork-Presbyterian and Weill Cornell Medicine who recently led the first fully robotic liver transplant in New York. Dr. Rocca details the recent developments in robotic surgery at Weill Cornell Medicine's Division of Liver Transplantation and Hepatobiliary Surgery, including an ongoing push to advance from laparoscopic and open surgical methods, and now to robotics. He explains why the robotic approach is optimal for complex liver surgeries and discusses how he and his team have been training to make robotic living donor hepatectomies a standard in their department. Then, Dr. Rocca breaks down the process of the liver transplant operation that became the first fully robotic execution in New York. He describes the most critical steps of the procedure, how it felt to achieve this milestone, and the example that he hopes to set for other institutions beyond NewYork-Presbyterian and Weill Cornell Medicine. © 2025 NewYork-Presbyterian

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Iris Wang, M.D. From symptom trackers to multidisciplinary app-based platforms, evidence-based digital therapeutics are expanding access to brain-gut behavioral care for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Dr. Peter Buch sits down with Dr. Iris Wang to discuss the spectrum of available tools and explore strategies for aligning them with individual patient needs. Dr. Wang is an Associate Professor of Medicine and the Associate Program Director of the Gastroenterology Fellowship at the Mayo Clinic in Rochester, Minnesota.

Guest: Thomas DeLoughery, MD Host: Peter Buch, MD, FACG, AGAF, FACP Iron deficiency anemia is common in gastroenterology patients and is often underrecognized or suboptimally managed. That's why targeted treatment is essential to improve patient outcomes. In this expert-led discussion, Dr. Peter Buch and Dr. Thomas DeLoughery outline what gastroenterologists need to know about oral vs IV iron, absorption dynamics, and tailoring therapy for various patient populations. Dr. DeLoughery is a Professor of Medicine in the Division of Hematology and Oncology at Oregon Health and Science University in Portland.

Guest: Francis Farraye, MD Host: Peter Buch, MD, FACG, AGAF, FACP A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author of this guideline, to highlight what clinicians need to know. Dr. Farraye is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Neena Abraham, MD, MS Knowing how to manage anticoagulants and antithrombotics during acute GI bleeding is essential in preventing avoidable complications, including thromboembolism and delayed hemostasis. Dr. Peter Buch sits down with Dr. Neena Abraham to discuss the latest recommendations from major GI and cardiology societies and explore practical strategies for anticoagulant reversal, triage criteria, and endoscopic hemostasis. Dr. Abraham is a Professor of Medicine and the Medical Director of the Cardiogastroenterology Clinic at the Mayo Clinic in Phoenix.

Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there's an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection. Reference: Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Ashwani K. Singal MD, MS, FACG, FAASLD, AGAF Sarcopenia and poor nutrition are often silent threats in chronic liver disease, yet they drastically impact outcomes. Joining Dr. Peter Buch to discuss strategies for recognizing and addressing malnutrition early to improve long-term liver health is Dr. Ashwani Singal. Dr. Singal is a Professor of Medicine at the University of Louisville School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Ashwani K. Singal MD, MS, FACG, FAASLD, AGAF Sarcopenia and poor nutrition are often silent threats in chronic liver disease, yet they drastically impact outcomes. Joining Dr. Peter Buch to discuss strategies for recognizing and addressing malnutrition early to improve long-term liver health is Dr. Ashwani Singal. Dr. Singal is a Professor of Medicine at the University of Louisville School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn's disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn's disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Stefan Holubar, MD, MS When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn's disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Stefan Holubar, MD, MS When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn's disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.

CME credits: 0.25 Valid until: 09-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-innovative-approaches-to-ibs-c-personalized-treatment-for-better-outcomes/27169/ Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. Do you know how to effectively treat IBS-C to increase your patients' quality of life? Tune in for an overview of the latest data.=

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/apoc3-inhibition-a-novel-approach-to-lowering-tgs/33222/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-road-ahead-whats-on-the-horizon-for-fcs-and-shtg-management/33228/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/targeting-mixed-hyperlipidemia-with-apoc3-inhibition/33227/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/remnant-cholesterol-the-missing-link-in-ascvd-risk/33226/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/shtg-defining-the-unmet-clinical-need/33224/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/latest-clinical-trial-outcomes-and-breakthroughs-for-fcs/33223/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/shtg-decoding-the-latest-clinical-trial-outcomes/33225/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-bar-guideline-recommended-treatment-in-hypertriglyceridemia/33221/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

CME credits: 1.00 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/fcs-enhancing-the-diagnosis/33220/ There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: J. Andy Tau, MD Topical hemostatic agents play a key role in managing complex bleeding cases, but there's a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: J. Andy Tau, MD Topical hemostatic agents play a key role in managing complex bleeding cases, but there's a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-first-line-treatment-on-subsequent-treatment-options-for-metastatic-escc/33031/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-navigating-first-line-treatment-selection-in-metastatic-escc/33029/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/ici-combination-regimens-for-first-line-treatment-of-metastatic-escc/33028/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored. Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

Guest: Elisa K. Boden, MD For many patients with Crohn's disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn's and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Elisa K. Boden, MD For patients with Crohn's disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it's still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Guest: Elisa K. Boden, MD For many patients with Crohn's disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn's and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.

Guest: Elisa K. Boden, MD For patients with Crohn's disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.

Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it's still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology's guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology's guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone's Inflammatory Bowel Disease Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD With so many therapeutic options for Crohn's disease and ulcerative colitis, it can be challenging to determine which one best matches your patient's needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD With so many therapeutic options for Crohn's disease and ulcerative colitis, it can be challenging to determine which one best matches your patient's needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone's Inflammatory Bowel Disease Center.